Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa

Inclusion Criteria

• •Availability for the entire study period and willingness to adhere to the protocol requirements as evidenced by the informed consent form (ICF) duly read, signed and dated by the volunteer prior to participation in the study.
• •Male or female volunteers.
• •Volunteers of at least 18 years of age but not older than 45 years.
• •Volunteers with body mass index (BMI) greater than or equal to 19 and below 30 kg/m2.
• •Volunteers who were healthy as determined by pre-study (at screening) medical history, physical examination, vital signs, complete neurological examination and 12-lead ECG.
• •Volunteers who had clinical laboratory test results judged clinically acceptable (within the laboratory's stated normal range; if not within this range, they must had been without any clinical significance) at screening and admission to first treatment period.
• •Volunteers who had negative tests for hepatitis B surface antigen (HBsAg), anti-hepatitis C antibodies (HCV Ab), and Human immunodeficiency viruses -1 and -2 antibodies (HIV-1 and HIV-2 Ab) at screening.
• •Volunteers who had negative screen of ethyl alcohol and drugs of abuse at screening.
• •Volunteers who were non- or ex-smokers. For the purpose of this study, an ex-smoker is defined as someone who completely stopped smoking for at least 3 months before day 1 of this study.
• •Due to unknown risks and potential harm to the unborn fetus, sexually active men or women must have agreed to use a medically acceptable form of contraception throughout the study.
• +32 more criteria